EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines Share
4 novembre 2022 – EMA’s safety committee (PRAC) has confirmed its recommendation to withdraw the marketing authorisations for amfepramone obesity medicines. This follows a re-examination of its previous recommendation of June 2022, which was requested by the companies that market these medicines.
For more information, see here.